EUVIMEDEUVIMED entdecken
Crossref

L26/P-459 Intra-cycle estradiol decline in PPOS: No adverse impact on oocyte competence, embryo development, or live birth rates in an exploratory cohort

Y. Mio, K. Yumoto, P. Tsounapi, M. Sugishima, T. Shimura, H. Yamaguchi, N. Tanabe, H. Kuwata, K. Yamada, N. Sumi, T. Ozaki

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von Y. Mio und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does terminal estradiol (E2) decline during progestin-primed ovarian stimulation (PPOS) negatively impact oocyte competence, embryo development, or live birth rates in patients undergoing ART cycles? Summary answer Intra-cycle E2 decline in PPOS does not impair oocyte maturation, embryo quality, or live birth rates, confirming that developmental competence is maintained despite terminal fluctuations. What is known already Since 2015, when PPOS was first introduced as a controlled ovarian hyperstimulation method to reduce ovarian-hyperstimulation syndrome, it has been shown to effectively prevent the activation and transmission phases of E2-induced luteinizing hormone (LH) surges, providing an alternative to conventional treatment with gonadotropin-releasing hormone (GnRH) analogues. However, a subset of PPOS cycles exhibits a perplexing dissociation: despite follicular development, serum E2 levels do not increase as expected. This hormonal uncoupling complicates follicular maturity assessment and ovulation timing, potentially impacting reproductive outcomes. To date, the impact of these terminal E2 fluctuations on embryological competence and clinical live birth rates remains poorly defined. Study design, size, duration This single-center retrospective study evaluated 222 stimulation cycles from 164 patients undergoing controlled ovarian hyperstimulation with the PPOS protocol between March 2023 and March 2024. Serum E2 concentrations were longitudinally monitored, specifically comparing baseline levels to the final monitoring visit prior to trigger. This design facilitated a comprehensive assessment of the impact of intra-cycle E2 fluctuations on laboratory and clinical outcomes. Participants/materials, setting, methods Patients were stratified into two cohorts based on terminal E2 trajectories: the E2-Elevation (optimal rise) and the E2-Decline (decrease). Primary outcomes included number of retrieved oocytes, maturation rate, normal fertilization rate (2PN zygotes), and blastulation rate. To ensure protocol integrity, LH dynamics were mapped from baseline to trigger-day to confirm effective hypothalamic suppression. Secondary endpoints included clinical pregnancy and live birth rates to evaluate the developmental potential of resulting embryos. Main results and the role of chance Within the study population (n = 222), 34.7% of patients exhibited a terminal E2-Decline, while 65.3% demonstrated an E2-Elevation. Baseline demographics, including age (36.1±5.6 vs. 36.0±5.6 years, respectively), AMH (4.2±3.8 vs. 5.1±4.4 ng/mL, respectively), and BMI, were comparable between the two cohorts (P>0.05). Notably, the number of retrieved oocytes did not demonstrate significant difference (10.7±6.9 in E2-Decline group vs. 13.3±8.3 in E2-Elevation group; P > 0.05). Embryological competence, between E2-Decline group and E2-Elevation group, remained equivalent across all key metrics: oocyte maturation rate (77.2% vs. 80.9%, respectively; P>0.05), fertilization rate (74.0% vs. 74.7%, respectively; P>0.05), and blastulation rate (56.1% vs. 58.9%, respectively; P>0.05). Although LH levels were lower in the E2-Decline cohort compared to the E2-Elevation at both baseline (0.7±0.6 vs. 2.6±1.9 mIU/mL, respectively) and trigger (4.2±3.0 vs. 5.0±3.0 mIU/mL, respectively), these differences were not statistically significant (P > 0.05) nor associated with compromised embryological or clinical success. Crucially, clinical outcomes reached comparable benchmarks, with live birth rates [72.7% (E2-Decline) vs. 68.8% (E2-Decline) and miscarriage rates [27.3% (E2-Decline) vs. 31.2%(E2-Decline)] showing no statistical difference. These findings suggest that a terminal E2 decrease during PPOS does not reflect follicular atresia or impaired developmental competence, supporting the continued progression of these cycles toward oocyte retrieval and subsequent transfer. Limitations, reasons for caution While this exploratory study identifies an E2 decline within PPOS protocols, its retrospective nature and sample size necessitate cautious interpretation. Prospective, multi-center investigations are warranted to elucidate the underlying physiological mechanisms and further validate the impact of these hormonal trajectories on long-term follicular and embryonic competence. Wider implications of the findings These findings suggest that terminal E2 decline does not signify follicular atresia or compromised cycle efficacy. Consequently, clinicians may proceed with planned oocyte retrieval without altering protocols. While the underlying physiological mechanism remains to be elucidated, this study provides crucial reassurance that such hormonal fluctuations do not necessitate cycle cancellation. Trial registration number No

Zitieren

APA

Mio, Y., Yumoto, K., Tsounapi, P., Sugishima, M., Shimura, T., Yamaguchi, H., Tanabe, N., Kuwata, H., Yamada, K., Sumi, N., & Ozaki, T. (2026). L26/P-459 Intra-cycle estradiol decline in PPOS: No adverse impact on oocyte competence, embryo development, or live birth rates in an exploratory cohort. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.793

Vancouver

Mio Y, Yumoto K, Tsounapi P, Sugishima M, Shimura T, Yamaguchi H, et al. L26/P-459 Intra-cycle estradiol decline in PPOS: No adverse impact on oocyte competence, embryo development, or live birth rates in an exploratory cohort. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.793

BibTeX
@article{Mio2026,
  author = {Mio, Y. and Yumoto, K. and Tsounapi, P. and Sugishima, M. and Shimura, T. and Yamaguchi, H. and Tanabe, N. and Kuwata, H. and Yamada, K. and Sumi, N. and Ozaki, T.},
  title = {L26/P-459 Intra-cycle estradiol decline in PPOS: No adverse impact on oocyte competence, embryo development, or live birth rates in an exploratory cohort},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.793}
}
Kostenlos starten →